MMR vaccination and disease elimination: the Finnish experience

References

• Peltola H, Karanko V, Kurki T et al. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland. Lancet1(8473), 137–139 (1986).
   PubMed Web of Science ®Google Scholar
• Peltola H, Heinonen OP, Valle M et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N. Engl. J. Med.331(21), 1397–1402 (1994).
   PubMed Web of Science ®Google Scholar
• Paunio M, Virtanen M, Peltola H et al. Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland. Am. J. Epidemiol.133(11), 1152–1160 (1991).
   PubMed Web of Science ®Google Scholar
• Leino T, Koskenniemi E, Saranpää P-R, Strömberg N, Kilpi T. The vaccination coverage continues top high. Suom Lääkäril (J. Finn. Med. Assoc.)62(8), 739–743 (2007).
   Google Scholar
• Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M, Heinonen OP. Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccinees. Am. J. Epidemiol.148(11), 1103–1110 (1998).
   PubMed Web of Science ®Google Scholar
• Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M, Heinonen OP. Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine. J. Epidemiol. Community Health53(3), 173–178 (1999).
   PubMed Web of Science ®Google Scholar
• Paunio M, Hedman K, Davidkin I et al. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol. Infect.124(2), 263–271 (2000).
   PubMed Web of Science ®Google Scholar
• Davidkin I, Valle M, Peltola H et al. Etiology of measles- and rubella-like illnesses in measles, mumps, and rubella-vaccinated children. J. Infect. Dis.178(6), 1567–1570 (1998).
   PubMed Web of Science ®Google Scholar
• Davidkin I, Jokinen S, Paananen A, Leinikki P, Peltola H. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. J. Infect. Dis.191(5), 719–723 (2005).
   PubMed Web of Science ®Google Scholar
• Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect. Dis.8(12), 796–803 (2008).
   PubMed Web of Science ®Google Scholar
• Koskiniemi M, Vaheri A. Effect of measles, mumps, rubella vaccination on pattern of encephalitis in children. Lancet1(8628), 31–34 (1989).
   PubMed Web of Science ®Google Scholar
• Ukkonen P. Rubella immunity and morbidity: impact of different vaccination programs in Finland 1979–1992. Scand. J. Infect. Dis.28(1), 31–35 (1996).
   PubMed Web of Science ®Google Scholar
• Peltola H, Davidkin I, Valle M et al. No measles in Finland. Lancet350(9088), 1364–1365 (1997).
   PubMed Web of Science ®Google Scholar
• Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA284(20), 2643–2647 (2000).
   PubMed Web of Science ®Google Scholar
• Progress in global measles control and mortality reduction, 2000–2007. Wkly Epidemiol. Rec.83(49), 441–448 (2008).
   PubMedGoogle Scholar
• Peltola H, Heinonen OP. Frequency of true adverse reactions to measles–mumps–rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet1(8487), 939–942 (1986).
   PubMed Web of Science ®Google Scholar
• Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles–mumps–rubella vaccination. Pediatrics106(5), E62 (2000).
   PubMed Web of Science ®Google Scholar
• Juntunen-Backman K, Peltola H, Backman A, Salo OP. Safe immunization of allergic children against measles, mumps, and rubella. Am. J. Dis. Child.141(10), 1103–1105 (1987).
   PubMedGoogle Scholar
• Patja A, Mäkinen-Kiljunen S, Davidkin I, Paunio M, Peltola H. Allergic reactions to measles–mumps–rubella vaccination. Pediatrics107(2), E27 (2001).
   PubMed Web of Science ®Google Scholar
• Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H. Serious adverse events after measles–mumps–rubella vaccination during a fourteen-year prospective follow-up. Pediatr. Infect. Dis. J.19(12), 1127–1134 (2000).
   PubMed Web of Science ®Google Scholar
• Patja A, Paunio M, Kinnunen E, Junttila O, Hovi T, Peltola H. Risk of Guillain–Barre syndrome after measles–mumps–rubella vaccination. J. Pediatr.138(2), 250–254 (2001).
   PubMed Web of Science ®Google Scholar
• Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet351(9112), 1327–1328 (1998).
   PubMed Web of Science ®Google Scholar
• Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Vaccine13(16), 1617–1622 (1995).
   PubMed Web of Science ®Google Scholar
• Davidkin I, Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine16(20), 2052–2057 (1998).
   PubMed Web of Science ®Google Scholar
• Davidkin I, Peltola H, Leinikki P, Valle M. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Vaccine18(27), 3106–3112 (2000).
   PubMed Web of Science ®Google Scholar
• Davidkin I, Jokinen S, Broman M, Peltola H. 25-year follow-up of measles, mumps and rubella antibodies in MMR vaccinated cohort. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington DC, USA, 25–28 October 2008.
   Google Scholar
• Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J. Infect. Dis.197(7), 950–956 (2008).
   PubMed Web of Science ®Google Scholar
• Mauldin J, Carbone K, Hsu H, Yolken R, Rubin S. Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays. J. Clin. Microbiol.43(9), 4847–4851 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen BJ, Doblas D, Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine26(50), 6392–6397 (2008).
   PubMed Web of Science ®Google Scholar
• Jokinen S, Österlund P, Julkunen I, Davidkin I. Cellular immunity to mumps virus in young adults 21 years after measles–mumps–rubella vaccination. J. Infect. Dis.196(6), 861–867 (2007).
   PubMed Web of Science ®Google Scholar
• Bangor-Jones RD, Dowse GK, Giele CM, van Buynder PG, Hodge MM, Whitty MM. A prolonged mumps outbreak among highly vaccinated aboriginal people in the Kimberley region of Western Australia. Med. J. Aust.191(7), 398–401 (2009).
   PubMed Web of Science ®Google Scholar
• Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: a historical perspective on unexpected elements. Vaccine27(44), 6186–6195 (2009).
   PubMed Web of Science ®Google Scholar
• Dayan GH, Quinlisk MP, Parker AA et al. Recent resurgence of mumps in the United States. N. Engl. J. Med.358(15), 1580–1589 (2008).
   PubMed Web of Science ®Google Scholar
• Brockhoff HJ, Mollema L, Sonder GJ et al. Mumps outbreak in a highly vaccinated student population, The Netherlands, 2004. Vaccine28(17), 2932–2936 (2010).
   PubMed Web of Science ®Google Scholar
• Sugerman DE, Barskey AE, Delea MG et al. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics125(4), 747–755 (2010).
   PubMed Web of Science ®Google Scholar
• Chen TH, Kutty P, Lowe LE et al. Measles outbreak associated with an international youth sporting event in the United States, 2007. Pediatr. Infect. Dis. J. DOI: 10.1097/INF.0b013e3181dbaacf (2010) (Epub ahead of print).
   Google Scholar
• Hahne S, te Wierik MJ, Mollema L et al. Measles outbreak, The Netherlands, 2008. Emerg. Infect. Dis.16(3), 567–569 (2010).
   PubMed Web of Science ®Google Scholar
• Follin P, Dotevall L, Jertborn M et al. Effective control measures limited measles outbreak after extensive nosocomial exposures in January–February 2008 in Gothenburg, Sweden. Euro Surveill.13(30), 18937 (2008).
   PubMedGoogle Scholar
• Dayan GH, Ortega-Sanchez IR, LeBaron CW, Quinlisk MP. The cost of containing one case of measles: the economic impact on the public health infrastructure – Iowa, 2004. Pediatrics116(1), E1–E4 (2005).
   PubMed Web of Science ®Google Scholar
• Das M, Pakarinen L, Ruotsalainen E et al. Imported measles cases in Finland – effective epidemiological action. Suom Lääkäril (J. Finn. Med. Ass.)64(7), 597–600 (2009).
   Google Scholar
• Dallaire F, De Serres G, Tremblay FW, Markowski F, Tipples G. Long-lasting measles outbreak affecting several unrelated networks of unvaccinated persons. J. Infect. Dis.200(10), 1602–1605 (2009).
   PubMed Web of Science ®Google Scholar
• Davidkin I, Broman M, Koskela P, Jokinen S. Impact of MMR vaccinations on measles, mumps and rubella antibody levels in the Finnish population. Presented at: ESCV 2008 Clinical Virology Annual Meeting. Saariselkä, Finland, 12–15 March 2008.
   Google Scholar
• Kremer JR, Schneider F, Muller CP. Waning antibodies in measles and rubella vaccinees – a longitudinal study. Vaccine24(14), 2594–2601 (2006).
   PubMed Web of Science ®Google Scholar
• LeBaron CW, Forghani B, Beck C et al. Persistence of mumps antibodies after 2 doses of measles–mumps–rubella vaccine. J. Infect. Dis.199(4), 552–560 (2009).
   PubMed Web of Science ®Google Scholar
• LeBaron CW, Forghani B, Matter L et al. Persistence of rubella antibodies after 2 doses of measles–mumps–rubella vaccine. J. Infect. Dis.200(6), 888–899 (2009).
   PubMed Web of Science ®Google Scholar
• Mossong J, O’Callaghan CJ, Ratnam S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine19(4–5), 523–529 (2000).
   PubMed Web of Science ®Google Scholar
• Mossong J, Muller CP. Modelling measles re-emergence as a result of waning of immunity in vaccinated populations. Vaccine21(31), 4597–4603 (2003).
   PubMed Web of Science ®Google Scholar
• Paunio M, Hedman K, Davidkin I, Peltola H. IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy. Expert Opin. Pharmacother.4(8), 1215–1225 (2003).
   PubMed Web of Science ®Google Scholar
• Muscat M, Bang H, Wohlfahrt J, Glismann S, Molbak K. Measles in Europe: an epidemiological assessment. Lancet373(9661), 383–389 (2009).
   PubMed Web of Science ®Google Scholar
• Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J. Infect. Dis.189(Suppl. 1), S1–S3 (2004).
   PubMedGoogle Scholar
• Global measles mortality, 2000–2008. MMWR Morb. Mortal. Wkly Rep.58(47), 1321–1326 (2009).
   PubMedGoogle Scholar
• Global reductions in measles mortality 2000–2008 and the risk of measles resurgence. Wkly Epidemiol. Rec.84(49), 509–516 (2009).
   PubMedGoogle Scholar
• Johansen K, Sjödin M, Westrell-Oskarsson L, Arneborn M, Akerlind B, Forsgren M. [Rubella still a problem in Europe – important that pregnant women have an adequate protection]. Lakartidningen101(49), 3994–3996, 3998–3999 (2004).
   PubMedGoogle Scholar
• Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. Br. Med. J.340, C1626 (2010).
   PubMed Web of Science ®Google Scholar
• Johansen K, Lopalco P. Passive immunity against measles in infants: is there a need for policy changes in the European vaccination schedules? Euro Surveill.12(9), E3–E4 (2007).
   Google Scholar
• Roberts C, Porter-Jones G, Crocker J, Hart J. Mumps outbreak on the island of Anglesey, North Wales, December 2008–January 2009. Euro Surveill.14(5) (2009).
   Google Scholar
• Marin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, Lebaron CW. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students – Iowa, 2006. Vaccine26(29–30), 3601–3607 (2008).
   PubMed Web of Science ®Google Scholar
• Cortese MM, Jordan HT, Curns AT et al. Mumps vaccine performance among university students during a mumps outbreak. Clin. Infect. Dis.46(8), 1172–1180 (2008).
   PubMed Web of Science ®Google Scholar
• Peltola H, Kulkarni PS, Kapre SV, Paunio M, Jadhav SS, Dhere RM. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin. Infect. Dis.45(4), 459–466 (2007).
   PubMed Web of Science ®Google Scholar
• Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin. Infect. Dis.47(11), 1458–1467 (2008).
   PubMed Web of Science ®Google Scholar
• Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Virusyhdistelmärokotuksen ensimmäiset 25 vuotta. Duodecim Med. J.124(12), 1371–1380 (2008) (In Finnish).
   Google Scholar